Results 1 to 10 of about 1,810,595 (288)

Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Molecular Therapy: Oncolytics, 2019
Cancer immunotherapy and the emergence of immune checkpoint inhibitors have markedly changed the treatment paradigm for many cancers. They function to disrupt cancer cell evasion of the immune response and activate sustained anti-tumor immunity ...
Venkatesh Sivanandam, Christopher J. LaRocca, Nanhai G. Chen, Yuman Fong, Susanne G. Warner   +4 more
doaj   +1 more source

Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.

PLoS ONE
BackgroundThe role of upfront cytoreductive nephrectomy remains debatable in the present era of tyrosine kinase inhibitors and immune checkpoint inhibitors.
Gu-Shun Lai, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang   +8 more
doaj   +1 more source

The Impact of Immune Checkpoint Inhibitors on Fertility Preservation and Pregnancy Outcomes

Journal of Education, Health and Sport
Immune checkpoint inhibitors have revolutionized cancer treatment by enhancing anti-tumor immune responses. However, their impact on fertility is an emerging concern, particularly among young patients, including children.
Agata Prokopiuk, Adrianna Tabeau, Agnieszka Pawlik, Patryk Dudek, Klaudia Łuczak, Wiktoria Ulicka, Justyna Pięta, Hanna Sitarek, Joanna Prus, Marcel Chudzikowski   +9 more
doaj   +1 more source

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

BMC Cancer, 2020
Background We describe the clinical benefit of immune checkpoint inhibitors using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and ASCO VF.
Fei Liang, Sheng Zhang, Qin Wang, Wenfeng Li   +3 more
doaj   +1 more source

Anti–PD-1-induced bullous pemphigoid in a renal transplant recipient

SAGE Open Medical Case Reports
Immune checkpoint inhibitors, particularly anti–PD-1 agents, are increasingly associated with bullous pemphigoid, a rare yet significant immune-related adverse event. We report a case of immune checkpoint inhibitor-induced bullous pemphigoid in a 74-year-
Ghassan Barnawi, Abby Johanna Kpata, Raghad Aldibane, Sarah Kashkari, Raquel Lazarowitz, Manish Khanna   +5 more
doaj   +1 more source

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Journal for ImmunoTherapy of Cancer, 2017
Background Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies.
Jose Lutzky, Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka   +5 more
doaj   +1 more source

A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors

Human Vaccines & Immunotherapeutics, 2017
Immune checkpoint inhibitors have revolutionized treatment of advanced cutaneous melanoma. This group of novel therapeutic agents differs from other systemic treatments and has necessitated a new approach for several fundamental aspects of clinical ...
Oren Levine, Tahira Devji, Feng Xie
doaj   +1 more source

Pathomechanism of immune checkpoint inhibitors-induced cardiotoxicity

Medycyna Paliatywna
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that work by blocking CTLA-4, PD-1 or PD-L1 molecules. They help activate the immune system to recognize and eliminate cancer cells. Immune checkpoint inhibitors are monoclonal antibodies that
Agata Kornacka, Emilia Babula, Agnieszka Floriańczyk, Agata Prokopiuk, Katarzyna Kołodziejczyk, Tomasz Dzierżanowski   +5 more
doaj   +1 more source

Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab

Scientific Reports
The clinical success of immune checkpoint inhibitors has underscored the key role of the immune system in controlling cancer. Current FDA-approved immune checkpoint inhibitors target the regulatory receptor pathways of cytotoxic T-cells to enhance their ...
Nicholas Lorig-Roach, Nina M. Harpell, Rebecca M. DuBois   +2 more
doaj   +1 more source

Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects

Frontiers in Immunology
Tumor cells can utilize the immune checkpoint pathway to inhibit T cell activation and evade the attack of tumor specific T cells. While immune checkpoint inhibitors (ICIs) competitively bind to checkpoint molecules to block checkpoint mediated ...
Jing Chen, Xue Cheng
doaj   +1 more source